[The kinetics of sulfamerazine (Mebacid) and the effect of sulfamerazine therapy on p-aminohippuric acid clearance in pregnancy].
Elimination half-life of Sulfamerazin (Mebacid) was not different in pregnant and non-pregnant women after a single oral dose and after 11 days repeated administration in therapeutic dosis. The initial concentrations of Sulfamerazin are lower in pregnants than in non-pregnants. Elimination half-life of p-aminohippurate (PAH) is shortened by Sulfamerazin-pretreatment, renal excretion of PAH is increased respectively.
D000328:Adult; D000618:Aminohippuric Acids / Q000652:urine*; D005260:Female; D006801:Humans; D007700:Kinetics; D011247:Pregnancy; D013416:Sulfamerazine / Q000008:administration & dosage / Q000378:metabolism*
D000618:Aminohippuric Acids; D013416:Sulfamerazine
Untersuchungen zur Kinetik von Sulfamerazin (Mebacid) und der Einfluss der Sulfamerazintherapie auf die p-Aminohippursäure-Clearance in der Schwangerschaft